Did Biogen's Kingsley Take Blame For Tecfidera Sales?
This article was originally published in Scrip
Executive Summary
The timing of Biogen's Oct. 9 announcement that Tony Kingsley, executive vice president of global commercial operations, is leaving the company came at an unfortunate time – just weeks before third quarter earnings will reveal whether Tecfidera (dimethyl fumarate) sales are growing, stable or sliding.
You may also be interested in...
Roche/Genentech Keeps Commitment To External Cancer Innovation
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
Amunix Raises $117m To Take Novel T-Cell Engager Into The Clinic
Amunix’s XTEN technology for half-life extension and precise drug delivery has been used by multiple partners over the past 15 years, but now the firm is building its own cancer therapy pipeline.
Finance Watch: Eleven Companies Reveal $1.45bn In $100m-Plus VC Deals
Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: